Tumor cell dissemination and micrometastases in breast cancer

被引:1
作者
Becker, S [1 ]
Fehm, T [1 ]
Becker-Pergola, G [1 ]
Wallwiener, D [1 ]
Solomayer, E [1 ]
机构
[1] Univ Tubingen, Frauenklin, D-72076 Tubingen, Germany
关键词
breast cancer; micrometastases; disseminated tumor cells; bone marrow; immunocytochemistry;
D O I
10.1055/s-2005-873023
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Despite primary curative therapy by surgery, chemo/hormone therapy and radiation therapy 20-40% of women diagnosed with breast cancer will suffer from a systemic recurrence of their disease within five to ten years, which is incurable. Current interpretation of research data supports the theory that tumor cell dissemination of subpopulations of the primary tumor must have occurred already at the time of primary therapy. Knowledge about these microdisseminated cells has significantly increased over the past few years. The aim of this article is to provide an overview of the latest advances of research in this area, as well as to provide a rationale for further studies. Phenotyping and genotyping could yield important insights into the biologic characteristics of disseminated tumor cells.
引用
收藏
页码:1141 / 1146
页数:6
相关论文
共 37 条
[1]  
Becker S, 2005, ANTICANCER RES, V25, P2171
[2]   Time is an important factor when processing samples for the detection of disseminated tumor cells in blood/bone marrow by reverse transcription-PCR [J].
Becker, S ;
Becker-Pergola, G ;
Fehm, T ;
Wallwiener, D ;
Solomayer, EF .
CLINICAL CHEMISTRY, 2004, 50 (04) :785-786
[3]  
BECKER S, 2004, CANC RES CLIN ONC S1, V130, P55
[4]  
BECKER S, 2004, CANC RES CLIN ONC S1, V130, P46
[5]   Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells [J].
Borgen, E ;
Naume, B ;
Nesland, JM ;
Kvalheim, G ;
Beiske, K ;
Fodstad, O ;
Diel, I ;
Solomayer, EF ;
Theocharous, P ;
Coombes, RC ;
Smith, BM ;
Wunder, E ;
Marolleau, JP ;
Garcia, J ;
Pantel, K .
CYTOTHERAPY, 1999, 1 (05) :377-388
[6]   Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. [J].
Braun, S ;
Pantel, K ;
Muller, P ;
Janni, W ;
Hepp, F ;
Kentenich, CRM ;
Gastroph, S ;
Wischnik, A ;
Dimpfl, T ;
Kindermann, G ;
Riethmuller, G ;
Schlimok, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (08) :525-533
[7]  
Braun S, 2001, CANCER RES, V61, P1890
[8]   Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients [J].
Braun, S ;
Kentenich, C ;
Janni, W ;
Hepp, F ;
de Waal, J ;
Willgeroth, F ;
Sommer, H ;
Pantel, K .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :80-86
[9]  
BRAUN S, 2003, BREAST CANC RES TR S, V67
[10]   Circulating tumor cells, disease progression, and survival in metastatic breast cancer [J].
Cristofanilli, M ;
Budd, GT ;
Ellis, MJ ;
Stopeck, A ;
Matera, J ;
Miller, MC ;
Reuben, JM ;
Doyle, GV ;
Allard, WJ ;
Terstappen, LWMM ;
Hayes, DF .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (08) :781-791